HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ERC-08-0017v1 15/4/1083    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pape, U.-F. Articles by Wiedenmann, B. Search for Related Content PubMed PubMed Citation Articles by Pape, U.-F. Articles by Wiedenmann, B.

¹ Department of Hepatology and Gastroenterology, Charité, Campus Virchow Klinikum² Institute for Social Medicine, Epidemiology and Health Economics, Charité, Campus Mitte³ Institute for Pathology, Charité, Campus Mitte, University Medicine Berlin, Berlin, Germany⁴ Department of Gastroenterology, Hepatology, Oncology and Infectious Diseases, Medical Clinic I, Markus Hospital, Frankfurt/Main, Germany

(Correspondence should be addressed to U-F Pape, Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; Email: ulrich-frank.pape{at}charite.de)

^* U-F Pape and U Berndt contributed equally to this work

Neuroendocrine tumours (NET) of the gastroenteropancreatic system comprise a malignant entity with a low incidence. Only limited information is available on long-term clinical outcome and clinically applicable prognostic factors. We performed a retrospective analysis of a large, well-characterized centre-based patient cohort of 399 patients with histologically proven NET. Data were analysed according to epidemiological, clinical and histopathological characteristics. Detailed survival analyses using the Kaplan–Meier method were performed. Prognostic factors were tested by log-rank testing and independent risk factors were analysed using a Cox regression model. In the studied cohort, primary tumours originated in the fore-, mid- and hindgut in 46.1, 37.1 and 4.5% respectively. Extra-intestinal or unknown primary tumours were present in 8.4 and 10.5% respectively. Distant metastasis was present at initial diagnosis in 69.4%. Most frequent metastatic sites were liver (85%), peritoneal cavity (18%), bones (8%), other intra-abdominal sites (6%) and lungs (4%). Overall, 5- and 10-year survival rates were 78 and 63% respectively. Time to progression after initial diagnosis was significantly shorter in pancreatic as compared with ileal NET. Survival analysis revealed significantly better clinical outcome for primary tumours smaller than 25 mm, absence of metastasis, absence of any clinical symptoms, positive immunohistochemical staining for chromogranin A and a lower Ki67 index. These results were confirmed as independent by multivariate analysis. Therefore, this large retrospective analysis of a well-documented cohort of patients with NET demonstrates several prognostic factors of clinical relevance and wide availability, which should be considered for risk stratification in the management of NET.

This article has been cited by other articles:

				A Ahmed, G Turner, B King, L Jones, D Culliford, D McCance, J Ardill, B T Johnston, G Poston, M Rees, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study Endocr. Relat. Cancer, September 1, 2009; 16(3): 885 - 894. [Abstract] [Full Text] [PDF]

				F. Ehehalt, H. D. Saeger, C. M. Schmidt, and R. Grutzmann Neuroendocrine Tumors of the Pancreas Oncologist, May 1, 2009; 14(5): 456 - 467. [Abstract] [Full Text] [PDF]